The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
This could be huge ! Results are better than what is out there currently ! Surely this has to be mega ?
Hi guys I bought £32k worth at £1.52 on Friday. See how it goes ! Nursing a loss at the moment but a company which I believe will reward me in the near future. Good luck to all those who are holding
Iamrich are you really rich. If everyone followed your £1 predictions would they also become rich ? If Yes when ??? Do you have a crystal ball ? Even the ghost has disappeared here !
Don’t be stupid ! A share price has no effect on what anybody says here !! What about all those talking about £5 £10 how come it hasn’t moved to that level ! This share is a traders dream at the moment. Great pumping and dumping in my opinion.
Yes a pattern developing ! Some punters getting mugged for their shares. Hold for gold !
Just bought £30k worth ! Let’s see what happens next !
What just happened the drop !
Over ! Will move up to new highs and beyond !
Yes deffo I agree. But don’t you think if we didn’t have the placing then we would be £3 plus right now ?
The price hasn’t moved up is because of the £2 placing ! Will be a over hang for a while in my opinion
What do you mean ?
Yes if not today then tomorrow ! Let’s live for the moment
He got his dollars at 1,45 it’s 1.41
Why 1,45 ? Surely 1.41 ?
Hey Casper ! Why Monday ? As Monday is the first
Yes In Sha Allah ! Bro I’ve picked a few more up today !
Ghost / Casper what’s your Twitter account
We believe an accurate, rapid antigen test, that has been appropriately validated, will help to limit the spread of the coronavirus and support the safe return to work and play. In the UK, the DHSC is a potential customer and partner in the roll out of such a validated test. While Avacta continues to be in dialogue with the DHSC, and with other organisations in the UK and abroad, with a view to future supply of its rapid antigen test, it is prioritising the full clinical validation of its nasal swab-based SARS-CoV-2 rapid antigen test as a pre-requisite for CE marking and broad commercialisation.
The Group will update the market fully through the appropriate channels as it reaches significant commercial and technical milestones.
Going back up ! Market makers have filled their boots and bought off weak holders Good luck all
at all it’s $4.26 after hours ! Have faith guys. This share will deliver. GLA